Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Standard Lithium Ltd — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.63 (market cap $6.04B), while Standard Lithium Ltd trades at $1.58 (market cap $398.07M). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 15.2× Standard Lithium Ltd's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Standard Lithium Ltd for 23 Days on average.
| IOVA | SLI | |
|---|---|---|
Market Cap | $6.04B | $398.07M |
Volume | 14,805,993 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $14.82 | $5.65 |
52-Week Low | $1.81 | $1.61 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $5.97B | $260.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Standard Lithium (SLI) trades at $1.58, down 4.24% today, with a bearish technical signal but bullish oscillators. The company shows negative profitability metrics with ROE at -15.55% and net income of -$48.40M for 2025, though recent quarterly EPS have beaten expectations. Positive developments include progress toward a final investment decision for the South West Arkansas lithium project by end of 2026 and expanded offtake agreements.
The outlook is mixed: analyst consensus is strongly bullish with a $3.83 price target (142% upside), but execution risks remain high as the company transitions to production. Key risks include project delays, funding needs, and negative cash flow from operations. The stock offers high potential reward but requires careful risk assessment given pre-revenue status.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
